Not Listed in material.This Company was mentioned in Adam's F list of companies and ASCO, but in 5/12 conf call they don't even mention or were asked about ASCO?? Anyway, they have Phase III results on their 20 mg PIN study to come out any day now..it is an indep study so GTXI has no idea..but on Feb they had a positive study result on Toremifene 80 mg (and this study is for 20 mg)..so could be fun, the drug basically is to help guys who have to take ADT for Prostate Cancer with weak bones and hot flashes..They are also partnered up with Merck for SARM collaboration but none of the data in either phase I or Phase II studies should be ready?? YET CUZ they don't have control over the data..I doubt that it would be given to them Thursday night to report with all the others..but maybe? Actually, the CEO in the cc today said as soon as he gets the data it's going out...Just, alittle background on this company-The company you need to know about is a small biotech from Memphis called GTx, Inc. (GTXI). Founded in 1997, the company’s hard work is just now beginning to pay off. This one is about to go from a small fish in a big pond to a competition-devouring piranha. GTx specializes in men’s health drugs. No, not the small blue pill, but the same general part of the body. One of the company’s most promising late-stage medicines is toremifene citrate, or Acapodene. It is used to help treat patients with advanced prostate cancer. Without getting too scientific, typical prostate cancer treatments are very hard on the body. They lower critical hormonal levels, destroy bone mass, and even degrade the heart. GTx’s potential new drug helps to eliminate many of those side effects. With nearly a million men currently undergoing treatment, Acapodene has a lot of potential. It is expected to hit the market later this year and bring the company as much as $400 million in annual revenues. Right now, GTx pulls in just $7 million. But remember I said I want at least two late-stage drugs in the pipeline and I want the Street to be talking. Acapodene will need some company if it wants to get my nod. It comes under the name Ostarine. Although it will be a bit longer before it hits the market, it offers even more potential than Acapodene. This is the drug most analysts and industry experts have their eyes on. Rumors are already flying… I love it. All of those potential drugs do not mean a thing, unless insiders are buying. GTx more than meets my requirements. So far this year, company insiders have shelled out more than

Stuck on this one...so unknown sex appeal..in 10Q..can't find any ASCO talk..R788-Product Candidate for B-Cell Lymphoma. Research has shown that overactivity of the signaling enzyme spleen tyrosine kinase, or Syk, appears to be an essential mechanism in several types of B-cell lymphoma proliferation and that R788 can inhibit the growth of B-cell lymphoma driven by Syk overactivity. In April 2007, we began enrolling patients in a multi-center, Phase 1/2 clinical trial to evaluate the safety and efficacy of R788 for the treatment of patients with B-cell lymphoma. The clinical trial has enrolled 80 patients at 11 major treatment centers in the United States and will focus on certain types of B-cell lymphomas. We expect to report interim results from this clinical trial in the first half of 2008. † R788-Product Candidate for Systemic Lupus Erythematosus (SLE or Lupus). Preclinical studies have also shown that R788 is highly effective in murine model of lupus. We expect to initiate a Phase 2 clinical trial in the second half of 2008. † R348-Product Candidate for RA and Other Immune Disorders. R348 is an orally-available potent, selective JAK3 inhibitor. JAK3 is a cytoplasmic tyrosine kinase that plays an important role in lymphocyte differentiation and proliferation in a variety of autoimmune diseases. We recently began enrolling patients in a Phase 1 clinical trial to evaluate the safety and tolerability of R348. We expect to complete dosing for this Phase 1 trial in the first half of 2008. † R763-Product Candidate for Oncology. R763/AS703569 is a potent, highly-selective, small-molecule inhibitor of aurora kinase. In October 2005, we signed a licensing agreement with Merck Serono that gave Merck Serono an exclusive license to develop and commercialize inhibitors in our aurora kinase program, including R763/AS703569. In November 2007, Merck Serono exercised its option to add Japan to the territories covered under the current aurora kinase collaboration with respect to R763/AS703569, resulting in a milestone payment to us of $3.0 million. Under the agreement, Merck Serono is responsible for the further development and commercialization of R763/AS703569. In September 2006, Merck Serono initiated a Phase 1 multi-center clinical trial to evaluate R763/AS703569 for the treatment of patients with refractory solid tumors. In February 2007, Merck Serono began an additional Phase 1 clinical trial evaluating R763/AS703569 on patients with hematological malignancies. Merck Serono has indicated that interim results from these Phase 1 clinical trials are expected in the second half of 2008. In July 2007, Merck Serono initiated its third Phase 1 clinical trial, designed to determine the maximum tolerated dose, safety and dosing regimen of R763/AS703569 in combination with gemcitabine, a commonly prescribed chemotherapeutic agent administered by intravenous infusion. The clinical trial will evaluate two different treatment regimens in which R763/AS703569 will be given in sequence with gemcitabine over 21-day cycles. As many as 72 patients with advanced malignancies, including pancreatic, ovarian, breast, non-small cell lung and colorectal, will be evaluated

THEY ARE STILL JUST TESTING STUFF..nothing yet..but it is looking good. SOUTH SAN FRANCISCO, Calif., May 15 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD - News), a biopharmaceutical company focused on oncology, today announced that the Company will present data from three clinical trials of picoplatin, in various tumor types and combinations, at poster sessions during the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) at McCormick Place in Chicago. The Company will present preliminary data from its ongoing Phase 2 clinical trial of picoplatin in colorectal cancer (CRC) and updated data from its Phase 1 CRC trial, data from its ongoing Phase 2 trial of picoplatin in hormone refractory prostate cancer (HRPC), as well as data from a Phase 1 trial of picoplatin in advanced solid tumors, including ovarian cancer. Picoplatin, the Company's lead product candidate, is a new generation platinum chemotherapy agent with the potential to become a platform product addressing multiple indications, administered either alone or in combination with other chemotherapy and targeted agents. "We are continuing to execute on our clinical strategy, demonstrating that picoplatin is a platform product, with broad utility in multiple solid tumor types," said Ronald Martell, president and chief operating officer of Poniard Pharmaceuticals. "The data from these trials that we will present at ASCO should illustrate the significant clinical value of picoplatin to patients with a broad range of tumor types, including those with colorectal, prostate and ovarian cancer. These results should be of significant interest to potential partners. The data being presented adds to the growing body of picoplatin data in over 750 patients, including in patients with small cell lung, colorectal, prostate and ovarian cancers." Poster presentation details are as follows: -- First-Line Treatment of Hormone Refractory Prostate Cancer: Abstract #5153 A Phase 2 study of picoplatin with docetaxel and prednisone in chemotherapy-naive patients with metastatic hormone-refractory prostate cancer (HRPC) Roman L, Karlov P, Cheporov S, Lopatkin N, Breitz H, Karlin D, Baker G. General Poster Session: Saturday, May 31, from 8 a.m. to 12 p.m. CDT S Hall A1, Poster #16A -- First-line Treatment of Colorectal Cancer: Abstract #4100 First-line Phase 1b and 2 studies of picoplatin in combination with 5-fluorouracil and leucovorin, FOLPI, as a potential neuropathy-sparing therapy for colorectal cancer Cheporov S, Gladkov O, Biakhov M, Breitz H, Karlin D, Baker G. General Poster Session: Monday, June 2, from 8 a.m. to 12 p.m. CDT S Hall A1, Poster #14B In addition, Don S. Dizon, M.D., assistant professor of obstetrics-gynecology and medicine at the Warren Alpert Medical School of Brown University, will present data from a Phase 1 trial of picoplatin in patients with ovarian cancer: -- Phase 1 Combination Study with Pegylated Liposomal Doxorubicin (including Ovarian Cancer): Abstract #2568, Final results of a Phase 1 study of picoplatin and pegylated liposomal doxorubicin in advanced solid tumor malignancies Dizon DS, Maluf F, Aghajanian CA, Daud A, Sabbatini P, Soignet S, Pezzulli S and Spriggs DR. General Poster Session: Sunday, June 1, from 2 p.m. to 6:00 p.m. CDT S Hall A1, Poster #12H 5153..Good..Results: 30 pts were enrolled and have received 1-10 cycles at this time. Of 22 pts currently evaluable for PSA response, 13 (59 %) achieved a PSA response, a >50% decrease in PSA maintained for at least 4 weeks. 9 pts have discontinued study treatment because of progressive disease and 2 due to SAEs unrelated to picoplatin. Combined safety data from Phase I and Phase II indicates the commonest adverse events are neutropenia, alopecia, thrombocytopenia, anemia and nausea. 12 pts have received >800 mg/m2. No neurotoxicity > grade 1 has been observed. Conclusions: Picoplatin at 120 mg/m2 can be safely administered with 75 mg/m2 docetaxel and prednisone. Preliminary PSA response data (59%) indicates potential improved efficacy of this novel combination in the treatment of patients with HRPC. Additional Phase II data is being evaluated in this study. 4100..Still on going..will get results later. Results: 59 pts have been treated in phase I FOLPI CRC studies to date. In the q4w schedule, 18 pts were studied and DLT, febrile neutropenia and thrombocytopenia, was observed at 180 mg/m2 in 2 of 6 pts. In the q2w schedule, 41 pts have been treated up to 120 mg/m2 and DLT has not been observed to date. Pts have received up to 24 cycles of Pico. 15 pts received a total Pico exposure of >600 mg/m2 and 7 have received >800 mg/m2. Mild neuropathy occurred in 9 pts, but no grade 3 or higher neuropathy was observed. Adverse events were primarily neutropenia, thrombocytopenia, nausea, asthenia and anorexia. The randomized Phase II study has enrolled 16/100 pts to date. Conclusions: The Phase I FOLPI study identified the MTD at 150 mg/m2 when Pico was infused every 4 wks with FU and LV. The DLT of Pico was hematological with no Grade 3 or 4 neuropathy. The Phase I FOLPI q2w study is ongoing with doses up to 120 mg/m2. Additional data is expected from the Phase I and ongoing Phase II studies. 2568..Further Studies..Background: Picoplatin is a novel, sterically hindered platinum(II) complex designed to circumvent mechanisms of platinum resistance. Given the single agent activity seen in multiple tumor types, we conducted a phase I study of picoplatin in combination with pegylated liposomal doxorubicin (PLD) in patients with advanced solid tumors. Methods: Patients with advanced solid tumors and a PS 0-2 who received up to three prior regimens for metastatic disease were eligible. Patients received picoplatin followed by PLD on day one of a 28-day cycle. Four dose levels were tested (picoplatin/PLD, mg/m2): 100/20, 100/30, 100/40, and 120/40. Results: Sixteen patients were enrolled (7M:9F) and all were evaluable for toxicity. The median age was 52 (range, 27-76). Diagnoses represented were as follows: ovarian (5), non-small cell lung (2), head and neck (2), bladder (2), and one each with mesothelioma, melanoma, thymic, peritoneal, and renal cell cancer. Sixty-two courses of treatment were delivered with a median of 4 cycles per patient (range, 1-7). The first three dose levels were well tolerated with minimal toxicity reported. At the fourth dose level (n=6), 2 experienced G3/4 leukopenia, 3 had G3/4 neutropenia, and 2/6 had G3/4 thrombocytopenia. Nonhematologic adverse events were mild with only one patient experiencing G3 constipation. Frequent nonhematologic toxicities included fatigue, stomatitis, hand-foot syndrome, nausea, vomiting, and constipation. Twelve patients were evaluable for response. Four patients (42%) responded (1CR, 4PR) and five (42%) had stable disease. Conclusions: Therapeutic doses of both picoplatin and PLD were administered with acceptable toxicity was demonstrated. The recommended phase II doses of picoplatin and PLD are 120 mg/m2 and 40 mg/m2, respectively. Given the preliminary activity, further clinical testing of this combination is warranted. Darn Risky Sexy..too small for BTS..I belive that if the ASCO news in June is positve on the phase II colorectal trial and the oral news and other news is also positive then we see the big boys jump in. I don't think the major insiders and players want this to drag out. Mc Mahon already made millions when he sold out a previous company to the big Pharma boys. He will do it again with pard. An out right sale of the company can take place without any shareholder vote because the insiders already control enough shares to sell out right the whole Company. There will be a deal done before the end of 08 IMO. At what price? My best guess would be $15.00 to $18.00 per share making Pard a market cap of somewhere around 600 million. This would be dirt cheap for BiG pharma. Remember when the first offer comes as either a possible partnering deal(I doubt this type deal) or a buy out, don't panic at the first and sell all your shares as this thiing could go into a real bidding war. If PICO is for real as we all think and it replaces all the other platinums now use for prostate and colorectal cancers as well as SCLC then the market for this product would be in the Billions world wide. That would then make the fair share price around $25.00/$30.00 Diver..

looks like Stage I went very well (as expected) and stage II was already announced that it is on it's way...IMGN...looks like a pass... Conclusions: The MTD and recommended phase II dose of T-DM1 given IV q3 wks is 3.6 mg/kg. At the MTD, gr >2 AEs related to T-DM1 have been infrequent and manageable. T-DM1 PK is compatible with q3-week dosing. Objective tumor responses have been observed at doses at or below the MTD. A phase II trial in advanced HER2+ BC pts who have progressed on a T-containing regimen is underway; weekly dosing is also being explored. VERY SEXY...Sendek reaffirmed a "Buy" rating with a $8 price target for Cambridge, Mass.-based Immunogen Inc., ahead of expected positive early-stage study data on Herceptin as a breast cancer treatment. There is an ongoing midstage study and matching data for both stages of development could prompt partner Genentech to accelerate development into Phase III clinical trials. Trastuzumab-DM1 (T-DM1) – This compound consists of our DM1 cell-killing agent attached to Genentech’s HER2-binding antibody, trastuzumab. It is in development by Genentech under an agreement that provides Genentech with the exclusive right to use our maytansinoid TAP technology with antibodies that target HER2. On April 10, 2008, Genentech disclosed that they plan to make a T-DM1 Phase III go/no go decision in 2008. They also disclosed that they expect to report T-DM1 Phase I data at the 2008 ASCO annual meeting. preview of the future of ImmunoGen (IMGN) began years ago when IMGN CEO Mitch Sayare had to beg the powers-that-be at Genentech (DNA) to try out ImmunoGen's ADC technology with HERCEPTIN, Genentech's flagship product for breast cancer. Sayare was loosely quoted as saying "I had to beg them to try it". Genentech then proceeded not to return his calls for about six months. DNA finally called back and said "let's make a deal". Then Genentech called back again and said, "let's make another deal, a bigger deal." That was a few years ago. Now we move to the present day. DNA announced data at the SABC in December 2007 on TRASTUZUMAB-MCC-DM1. The initial phase trial data didn't disappoint. 15 patients were dosed at MTD of 3.6mg/kg. 5 of the 15 patients dosed currently have had a PR (partial response) and 7 of 10 of those patients have SD (stable disease). That yields a response rate of 12 pts out of 15 dosed or 80%. How many chemo drugs get 80% RR? Few, if any, that I know of. Let me remind you that all of these patients had seen prior chemotherapy, in fact a median of three prior chemotherapy regimens. All suffered from incurable metastatic breast cancer, and all had been treated with and recently failed Herceptin prior to entry in this study. What does this mean for ImmunoGen? It means Genentech believes that its franchise oncology product, HERCEPTIN, now has its successor, TRASTUZUMAB-DM1. Why am I so confident, you ask? First, you have to listen to what Genentech says, and then what they do. Behind the scenes. First, Genentech laid out its production capabilities for TRASTUZUMAB-DM1 last fall, showing the world its hand. Genentech will move forward with this drug. Why so soon? When a drug works, you start planning ahead, and guess what? Genentech says it works. Then, Roche (RHHBY.PK), the majority owner of DNA, exercised its opt-in right to market trastuzumab-dm1, ex-US. In other words, Roche will market TRASTUZUMAB-DM1 worldwide, minus the US market. This is huge for ImmunoGen. Currently, Genentech is running two trials with TRASTUZUMAB-DM1 - a weekly phase 1 dosing schedule and an every 3 week phase 2 dosing schedule. I fully expect DNA to eventually broaden this current phase 1 dose escalation trial into a full phase 2 trial. Compare the data between the two trials. Both trials will show remarkable, superior efficacy for past herceptin trial failures and will lead Genentech to determine its pivotal trial dose and begin this pivotal trial in 2009. Enrollment is both trials is going well and I expect both trials to complete enrollment before year end 2008. Comparative trial Yet, this is what I thought of it in Jan...Very interesting, but not sexy. If you want to invest in ADCs this is probably your play. But this entire technology is so NEW and developing that there will be a lot set-backs. Market Cap is 166.28M but they have been getting partnerships/licensing from some heavy hitters (DNA,JNJ, Biogen,etc.). They should have some more of their phase 1 data in the middle of year.,,that is IMO901 which use to be HuN901-DMI-3. The field of ADCs is just beginning...ADC stands for antibody drug conjugate..it has 3 parts to it to fight cancer...1.Cell Killing Agent 2. Attachment 3.Antibody. Very cool way to fight cancer. For IMGN because they use a cleave process, this may be the end of their pipeline. DNA uses a non-cleave process. ***Watch for the ASH (American Society of Hematology) starting Dec 6-9 in San Fran in 2008.....Adam wrote this on 5/10.."Immunogen's near-term fortunes are likely tied to the work being done in partnership with Genentech (DNA - Cramer's Take - Stockpickr) on Trastuzumab-DM1 (T-DM1), which takes the breast cancer drug Herceptin and attaches to it a potent cancer-cell-killing agent. It is Immunogen's technology that secures the toxic payload to monoclonal antibodies like Herceptin. Look to the ASCO meeting next month for some new phase I data on T-DM1 to be presented. A phase II study is under way, with data expected in December. Genentech has also said it will make a go/no-go decision on a phase II Immunogen has a pipeline of its own proprietary cancer drugs, but the market isn't going to give them much credit until further progress is made with T-DM1. The Genentech go/no-go decision is key. So far, there hasn't been any indication that Genentech won't move forward into phase III, but you can't be sure until the announcement is made. I'd also expect Immunogen to raise money if T-DM1 moves forward and the stock pops as a result

Not Sexy at this point..can't find any buzz about ASCO out of them..in 10Q Oncology Oncology product revenue increased 33% to $22.3 million for the three months ended March 31, 2008, as compared to the same period of 2007, primarily due to the addition of sales of Clolar outside of North America, which rights we acquired in connection with our acquisition of Bioenvision in October 2007. In September 2007, the FDA approved expanded labeling for Campath to include first-line treatment of patients with B-cell chronic lymphocytic leukemia, or B-CLL, significantly increasing the number of patients eligible to receive the product. In December 2007 we received European approval for an expanded indication as well. We are developing the intravenous formulation of Clolar for significantly larger indications, including first-line and relapsed or refractory AML in adults. We are also developing an oral formulation of Clolar and have initiated clinical trials for the treatment of myelodysplastic syndrome, or MDS. Clolar has been granted orphan drug status for the treatment of ALL and AML in both the United States and European Union. 38

1. XL647 - there weren't any surprises here since Exelixis has been talking up this compound lately and the abstracts are congruent with their recent statements. XL647 may be a decent 2nd or 3rd line drug for NSCLC and there are signs that it would be a good 1st line drug for a certain sub-population of patients. 2. Fantastic results for XL880 for PRC. They had 20 of 20 patients showing benefit from the compound. The abstract for Gastric Cancer was not as clear. If I'm understanding it correctly 6 of 12 patients had stable disease and 2 of these had tumor shrinkage of 20%. 3. Fantastic results for XL184 for MTC. 10 of 10 patients had stable disease or better. I'm betting GSK will opt-in on this one later this year. I think the only reason they would pass is that MTC is not too common and they didn't believe that there are other indications where XL184 would be efficacious. 4. The abstract for XL765 was very preliminary. It showed that the compound was tolerated and that maximum tolerated dose has not yet been achieved. There were also signs of some activity for a patient with NSCLC and another with testicular cancer. I am hoping there will be more up-to-date efficacy information in 2 weeks. There should also be information on some other compounds (I forgot which they were) in a couple of weeks when Exelixis holds their press conference at the ASCO conference. Having a big miss..Not Sexy at all...For XL 6478053 Citation: J Clin Oncol 26: 2008 (May 20 suppl; abstr 8053) Author(s): N. A. Rizvi, M. G. Kris, V. A. Miller, L. M. Krug, S. Bekele, A. Dowlati, K. M. Rowland, R. Salgia, N. Aggarwal, S. M. Gadgeel Abstract: Background: XL647 is a small molecule inhibitor of EGFR, HER2, and VEGFR2. Oral administration of XL647 results in dose-dependent, sustained inhibition of these target enzymes in preclinical studies. Increasing evidence of a close relationship between EGFR- and VEGFR2-mediated signaling pathways suggests that simultaneous inhibition of these pathways may provide improved efficacy. Methods: XL647 is administered orally as a single dose of 350 mg on Days 1-5 of each 14 day cycle (intermittent cohort). A second cohort will receive 300 mg daily. The primary endpoint is tumor response by RECIST. Pts with previously untreated advanced NSCLC (Stage IIIB or Stage IV) with adenocarcinoma histology that meet at least one of the following demographic criteria: Asian, female, minimal ( 3 months was observed in a total of 36% of patients. Common adverse events reported to date are Grade 1/ 2 diarrhea, fatigue, rash, nausea and clinically asymptomatic QTc prolongation. Conclusions: This study supports a clinical selection strategy to enrich a NSCLC population for EGFR mutations. XL647 has anti- tumor activity in selected NSCLC pts, demonstrating a 28% PR rate and 36% SD for > 3 months, for an overall clinical benefit rate of 64%. All 8 pts with EGFR activating mutations experienced tumor shrinkage (7 with PRs and 1 SD). Three pts without an EGFR mutation experienced a PR. XL647 is well-tolerated in this patient population. Data from the daily dosing cohort will be presented... Second trial..50% failure..4572 Citation: J Clin Oncol 26: 2008 (May 20 suppl; abstr 4572) Author(s): M. P. Jhawer, H. L. Kindler, Z. A. Wainberg, J. R. Hecht, R. O. Kerr, J. M. Ford, C. Henderson, T. Mueller, H. N. Keer, M. A. Shah Abstract: Background: XL880 is a potent, orally available small molecule inhibitor of MET and VEGFR2/KDR. Gastric cancer cell lines with MET amplification at 7q31 are sensitive to MET inhibition. Since, in retrospective clinical series, 7q31 amplification has been associated with PDGC, this phase II study examines the safety and efficacy of XL880 in pts with metastatic PDGC. Methods: The primary endpoint is response rate (RR), with 30 pts required to test the hypothesis that the RECIST confirmed RR with XL880 is 29% with 81% power and type I error of.041, versus Ho RR 11%. Eligibility requirements include: 0-2 prior chemotherapy regimens, adequate organ function, measurable disease, and ECOG 0-2. Pts receive XL880 240 mg/day on d1-5 of 14 day treatment cycles, and response is assessed every 8 weeks. MET amplification, determined by FISH of archival tissue, is defined as > 3 copies of 7q31. Optional pre- and on-treatment tumor biopsies are analyzed by immunohistochemistry for XL880 effects on direct and downstream drug targets. Plasma markers are analyzed for effects of anti-angiogenic therapy including VEGF-A and sVEGFR2. XL880 pharmacokinetics are evaluated as well. Results: As of 12/28/07, 18 pts have enrolled, 16 with tumor available for FISH. XL880 was well tolerated: all AEs were grade 1 or 2, most commonly hypertension, nausea, anorexia, fatigue, and asymptomatic liver function abnormalities. No related grade 4 or 5 AEs have been observed. Four of 16 pts had MET amplification by FISH: 2 evaluable pts demonstrated 20% decrease in tumor size, one progressed prior to XL880 treatment initiation, and one has not yet had the first efficacy evaluation. Overall, of 12 evaluable pts 2 patients had 20% decrease in tumor size at the first 8-week evaluation. Of these 12 pts, 6 remain on study (2 for > 12 wks, 4 for 8+ wks) and 6 had disease progression at

This is what I wrote in Jan..it has been down 36% since then...Not Sexy..blew it...and not in a good way. Yes, they have more drugs and money in the pipeline but bad news came out in Dec..there melanoma drug didn't make the cut...oh well. http://www.forbes.com/2007/12/20/array-biopharma-melanoma-markets-equity-cx_ml_1220markets20.html?partner=yahootix

Genentech moves up timeline for Avastin trial Thu May 15, 2008 11:21pm EDT Email | Print | Share| Reprints | Single Page| Recommend (0) [-] Text [+] Related News Avastin improves brain cancer survival 9:24pm EST Study shows RAD001 froze kidney cancer for a year 8:23pm EST powered by Sphere Market News Nikkei rises for fifth day, led by exporters Oil's fall, techs' gain drive stocks higher | Video Sotheby's shares jump as Bacon artwork sells for record price | Video More Business & Investing News... Featured Broker sponsored link ¥ € $ - Learn. Practice. Trade.LOS ANGELES, May 15 (Reuters) - Genentech Inc (DNA.N: Quote, Profile, Research) said on Thursday a trial of Avastin in colon cancer patients who have undergone surgery will be completed earlier than expected due to faster collection of data and a higher-than-planned number of patients with stage III cancer. Final results from the trial, which is being conducted by the National Surgical Adjuvant Breast and Bowel Project, are expected next year, rather than in 2010, the company said. Genentech said the update does not change its assessment of the Phase III study's probability of success. The trial involves more than 2,700 patients with stage II and III cancer. The company also said the last interim independent assessment of the study took place in the second quarter of this year and found no new or unexpected safety events. Genentech said the incidence of non-cancer-related deaths was similar between the treatment arms and consistent with prior Phase III adjuvant colon cancer trials. No significant increases in gastrointestinal perforation, hemorrhage, arterial or venous thrombotic events or deaths were observed in the Avastin part of the trial. The safety results will be presented at the May 30 to June 3 annual meeting of the American Society of Clinical Oncology. DNA will announce positive Avastin data at ASCO May 30th, it could be up in the high $80s ez .. Genentech: I know, it’s boring to mention these guys in an ASCO preview story, because the company is always there with a big presence. Avastin, Avastin, Avastin. True enough, and this year will be no different. The early headline this year is that we’ll see the actual data from the positive AVADO trial of Avastin in first-line metastatic breast cancer patients. The fact that the FDA approved Avastin for these patients last month takes some of the surprise out of the ASCO data presentation, but it will still be important.